Home › Research › Digital health tools
Treatment of frontotemporal dementia
Tsai RM, Boxer AL.. Current treatment options in neurology, 2014-11-01
Topic: Risk, prevention and care in population studies
Each syndrome can be associated with one or more underlying neuropathological diagnoses and are referred to as frontotemporal lobar degeneration (FTLD). Motor difficulties associated with FTD may present with parkinsonian symptoms or motor neuron disease, for which riluzole is indicated as therapy. Compared to idiopathic Parkinson's disease, FTD-related atypical parkinsonism is generally not responsive to dopamine replacement therapies, but a small percentage of patients may experience improvement with a trial of carbidopa-levodopa. Speech therapy may also help patients manage symptoms associated with aphasia, apraxia, and dysarthria.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tsai, R. M., & Boxer, A. L. (2014). Treatment of frontotemporal dementia. Current treatment options in neurology. https://doi.org/10.1007/s11940-014-0319-0
Vancouver
Tsai RM, Boxer AL. Treatment of frontotemporal dementia. Current treatment options in neurology. 2014. doi:10.1007/s11940-014-0319-0. PMID: 25238733.
BibTeX
@article{tsai2014-25238733,
author = {Tsai, R. M. and Boxer, A. L.},
title = {{Treatment of frontotemporal dementia}},
journal = {Current treatment options in neurology},
year = {2014},
doi = {10.1007/s11940-014-0319-0},
pmid = {25238733},
url = {https://doi.org/10.1007/s11940-014-0319-0}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Each syndrome can be associated with one or more underlying neuropathological diagnoses and are referred to as frontotemporal lobar degeneration (FTLD).
- Motor difficulties associated with FTD may present with parkinsonian symptoms or motor neuron disease, for which riluzole is indicated as therapy.
- Compared to idiopathic Parkinson's disease, FTD-related atypical parkinsonism is generally not responsive to dopamine replacement therapies, but a small percentage of patients may experience improvement with a trial of carbidopa-levodopa.
- Speech therapy may also help patients manage symptoms associated with aphasia, apraxia, and dysarthria.
Why it matters
For frontotemporal dementia, riluzole is indicated for motor neuron disease symptoms, and a small percentage of patients may improve with a trial of carbidopa-levodopa, though FTD-related parkinsonism is generally not responsive to dopamine replacement. Speech therapy may help manage aphasia, apraxia, and dysarthria symptoms.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Evidence strengthHigh
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current treatment options in neurology) |
| Journal's citation record | 1 / 4 | Current Treatment Options in Neurology: journal h-index 77 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 98 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.0 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 3 / 6 | Cited 3.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 2 / 4 | Cited 25 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Adam L. Boxer: h-index 98 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, San Francisco: institution h-index 1,915 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25238733) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Digital health tools
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.